IMMATICS NV

Perceptive Advisors’ recent purchase of 863k Immatics NV shares signals growing investor confidence in its immunotherapy pipeline and fresh capital, hinting at strong upside potential for the biotech.

Immatics insider Pepin James Nelson buys 181,200 options and 43,800 RSUs, signaling confidence in the biotech’s pipeline and future upside.

Explore Immatics NV insider option activity—key leaders’ long‑term stake, potential dilution, and what it means for investors in this biotech leader.

Explore Immatics NV’s insider activity: fully vested options to 2035, market rally, and long‑term executive alignment insights.

Weinschenk’s long‑term stock‑option plan shows Immatics NV insiders staying aligned with the company’s growth, boosting investor confidence.